Stocks · News reference
EXCLUSIVE: Sunshine Biopharma Reports Preclinical Tumor Suppression with K1.1 mRNA in Liver Cancer; Advances mRNA-Cancer Vaccine for Difficult-to-Treat Lung Cancer
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Sunshine Biopharma Announces Updates On Its K1.1 mRNA Tumor Suppressor; Outlines Plans For Program
Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a leading pharmaceutical company offering and researching life-saving medicines across multiple therapeutic areas including oncology and antivirals, today
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer
Sunshine Biopharma outlines K1.1 mRNA pipeline updates, advancing dual oncology therapy to target cold tumors in liver and lung cancer.